Insight

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors – ASCO

Collage of G Curigliano and Aditya Bardia

Oct 5, 2024, 09:20

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors – ASCO

ASCO shared a post on X:

“Experts Giuseppe Curigliano & Aditya Bardia discuss the results of the DESTINY-Breast06 trial, which showed significant PFS improvement with T-DXd in pts with HR+, HER2-low metastatic.”

DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive Metastatic Breast Cancer. How Do These Results Impact Practice for All Patients?

Authors: Giuseppe Curiglian and Aditya Bardia

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors - ASCO

Source: ASCO/X

Aditya Bardia ASCO Breast Cancer cancer cancer awareness cancer care DESTINY-Breast06 fight against cancer Giuseppe Curigliano Global fight against cancer OncoDaily Oncology

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

Eric Bouffet: New hope for children and adults with hemianopia

Devora Kestel: The official launch of the new WHO and UNICEF Service Guidance on Mental Health for Children and Young People

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Special Coverage